These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32458702)

  • 21. HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
    Ben-Baruch NE; Bose R; Kavuri SM; Ma CX; Ellis MJ
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1061-4. PubMed ID: 26358790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Acquired
    Hanker AB; Brewer MR; Sheehan JH; Koch JP; Sliwoski GR; Nagy R; Lanman R; Berger MF; Hyman DM; Solit DB; He J; Miller V; Cutler RE; Lalani AS; Cross D; Lovly CM; Meiler J; Arteaga CL
    Cancer Discov; 2017 Jun; 7(6):575-585. PubMed ID: 28274957
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis.
    Nasrazadani A; Brufsky A
    Future Oncol; 2020 Mar; 16(7):247-254. PubMed ID: 32057254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
    Kotecki N; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
    [No Abstract]   [Full Text] [Related]  

  • 26. Optimal treatment of early stage HER2-positive breast cancer.
    Pernas S; Barroso-Sousa R; Tolaney SM
    Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.
    Awada A; Dirix L; Manso Sanchez L; Xu B; Luu T; Diéras V; Hershman DL; Agrapart V; Ananthakrishnan R; Staroslawska E
    Ann Oncol; 2013 Jan; 24(1):109-16. PubMed ID: 22967996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Chilà G; Guarini V; Galizia D; Geuna E; Montemurro F
    Drug Des Devel Ther; 2021; 15():2711-2720. PubMed ID: 34188449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW; Liu MC; Yee D; Yau C; van 't Veer LJ; Symmans WF; Paoloni M; Perlmutter J; Hylton NM; Hogarth M; DeMichele A; Buxton MB; Chien AJ; Wallace AM; Boughey JC; Haddad TC; Chui SY; Kemmer KA; Kaplan HG; Isaacs C; Nanda R; Tripathy D; Albain KS; Edmiston KK; Elias AD; Northfelt DW; Pusztai L; Moulder SL; Lang JE; Viscusi RK; Euhus DM; Haley BB; Khan QJ; Wood WC; Melisko M; Schwab R; Helsten T; Lyandres J; Davis SE; Hirst GL; Sanil A; Esserman LJ; Berry DA;
    N Engl J Med; 2016 Jul; 375(1):11-22. PubMed ID: 27406346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of dual targeting in HER2-positive breast cancer.
    Kümler I; Tuxen MK; Nielsen DL
    Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells.
    Zhang Y; Zhang J; Liu C; Du S; Feng L; Luan X; Zhang Y; Shi Y; Wang T; Wu Y; Cheng W; Meng S; Li M; Liu H
    Cancer Lett; 2016 Nov; 382(2):176-185. PubMed ID: 27597738
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
    Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
    J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimal Strategies for Successful Initiation of Neratinib in Patients with HER2-Positive Breast Cancer.
    Jackisch C; Barcenas CH; Bartsch R; Palma JD; Glück S; Harbeck N; Macedo G; O'Shaughnessy J; Pistilli B; Ruiz-Borrego M; Rugo HS
    Clin Breast Cancer; 2021 Oct; 21(5):e575-e583. PubMed ID: 33678567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.
    Burstein HJ; Sun Y; Dirix LY; Jiang Z; Paridaens R; Tan AR; Awada A; Ranade A; Jiao S; Schwartz G; Abbas R; Powell C; Turnbull K; Vermette J; Zacharchuk C; Badwe R
    J Clin Oncol; 2010 Mar; 28(8):1301-7. PubMed ID: 20142587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond trastuzumab: new treatment options for HER2-positive breast cancer.
    Saini KS; Azim HA; Metzger-Filho O; Loi S; Sotiriou C; de Azambuja E; Piccart M
    Breast; 2011 Oct; 20 Suppl 3():S20-7. PubMed ID: 22015288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neratinib Approved for HER2+ Breast Cancer.
    Cancer Discov; 2017 Sep; 7(9):OF1. PubMed ID: 28778899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. When to Add Additional Anti-HER2 Therapy to Adjuvant Trastuzumab.
    Zimmer AS; Denduluri N
    Curr Oncol Rep; 2019 Nov; 21(12):109. PubMed ID: 31781874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.
    Li J; Fu F; Yu L; Huang M; Lin Y; Mei Q; Lv J; Wang C
    Breast Cancer Res Treat; 2020 Feb; 180(1):21-32. PubMed ID: 31970560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.
    Canonici A; Ivers L; Conlon NT; Pedersen K; Gaynor N; Browne BC; O'Brien NA; Gullo G; Collins DM; O'Donovan N; Crown J
    Invest New Drugs; 2019 Jun; 37(3):441-451. PubMed ID: 30062574
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.